Skip to main content
. 2020 Sep 24;12(10):2746. doi: 10.3390/cancers12102746

Figure 4.

Figure 4

Schematic diagram summarizing the effect of target therapy on hepatic CSCs. CD133 antibody conjugated to a cytotoxic drug (monomethyl auristatin F), transcription factor inhibitor Ikaros, and Akt signaling inhibitor with 5-FU reduced the self-renewal capacity of CD133+ hepatic CSCs. All-trans retinoic acid (ATRA) with cisplatin, Oncostatin M (OSM), EpCAM-blocking antibodies (Adecatumumab and Catumaxomab), and EpCAM blocking RNA interference (RNAi) inhibited the self-renewal capacity of CD133+ hepatic CSCs. In addition, anti-CD44 antibody prevented the tumor formation and metastasis of CD44-positive hepatic CSCs.